GILD logo

Gilead Sciences

GILD · What the business does, what can go wrong, and how options sellers approach it

What it does

Gilead Sciences is a biopharmaceutical company that develops and sells medicines, with a long focus on infectious diseases. Its core business is treatment and prevention of HIV, along with therapies for hepatitis B and hepatitis C. It also has a growing oncology business, which includes cell therapies from its Kite unit and an antibody-drug conjugate for certain breast cancers. It also has a liver disease and inflammation presence.

How it makes money

Gilead earns most of its revenue from selling prescription drugs to wholesalers, pharmacies and hospitals, in the United States and abroad. HIV products make up the largest share of sales. Revenue depends on patent-protected drugs, negotiated prices with insurers and government programs, and ongoing prescription volumes. Oncology and other areas add smaller but important streams.

Why investors own it

  • Established cash generation: Its HIV franchise has been a long-running source of cash flow.
  • Dividend: The company has paid a regular dividend, which appeals to income-focused holders.
  • Pipeline optionality: Oncology, HIV prevention and other research programs could add new products over time.
  • Sector role: Large biopharma is often held for its relative stability compared with smaller biotech.

What can go wrong

  • Patent expiration: Key drugs eventually face generic competition, which can cut sales sharply.
  • Pricing pressure: Governments and insurers can push for lower drug prices.
  • Pipeline setbacks: Clinical trials can fail, and acquired programs may not deliver.
  • Concentration: A heavy reliance on HIV means problems there affect the whole company.
  • Competition: Rival therapies, including long-acting treatments, can take share.
  • Acquisition risk: Purchased businesses may not earn back what was paid.

What to watch

  • HIV treatment and prevention sales trends
  • Oncology product growth, including cell therapy and Trodelvy
  • Clinical trial results and regulatory decisions
  • Patent and exclusivity timelines
  • Drug pricing and reimbursement policy changes
  • Dividend declarations and business development activity
  • Management guidance for the year

Options income angle

Options on GILD are generally liquid, with many strikes and expirations, especially near the current share price. Implied volatility tends to be modest compared with smaller biotech names, but it often rises ahead of earnings, major trial readouts, regulatory decisions and drug pricing news.

One caution for anyone selling premium: a sudden event, such as a failed trial or a policy shift, can move the stock sharply and quickly. Covered calls can cap upside, and cash-secured puts can lead to buying shares at a loss relative to the market price. Dividend dates also matter, since early assignment on short calls can happen around them.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 24, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Gilead's 2025 revenue grew 2% to $29.4 billion, led by HIV. Net income rose to $8.5 billion from $480 million, mainly because two large 2024 charges did not repeat. The filing also says Biktarvy, the company's largest product, was selected for Medicare price negotiation, with new prices effective beginning in 2028.

How the business did

  • HIV product sales increased 6% to $20.8 billion on higher demand for treatment and prevention. Biktarvy rose 7% and Descovy rose 31%. Liver Disease sales rose 6% to $3.2 billion.
  • Veklury, the COVID-19 drug, fell 49% to $911 million on lower COVID-19-related hospitalizations. Cell Therapy fell 7% to $1.8 billion, which management attributed to ongoing competitive headwinds.
  • Diluted earnings per share were $6.78, versus $0.38 in 2024. The 2024 results carried a $3.8 billion acquired in-process R&D expense (the cost of buying drug candidates still in development) for the CymaBay deal. They also carried a $4.2 billion impairment, a write-down of an asset's recorded value, tied to Trodelvy in lung cancer. In 2025 the impairment was $590 million, on the bulevirtide asset from the MYR acquisition. Higher net unrealized gains on equity securities also helped.
  • Discounts and rebates took 41% of gross product sales, up from 38%, mainly because of the Medicare Part D redesign.
  • Operating cash flow was $10,019 million, versus $10,828 million in 2024. The company paid $4.0 billion in dividends, $1.9 billion for share repurchases and $1.8 billion to repay debt.

Risks specific to this company

  • HIV dependence: A substantial portion of revenue comes from HIV products. Generic competition or a failure to launch new HIV medicines could force cuts to R&D spending.
  • Biktarvy pricing: The filing expects the negotiated Medicare price to be substantially lower than the current price. It could also raise Medicaid rebates and lower 340B ceiling prices, which are the discounted prices charged to certain safety-net healthcare providers.
  • Washington policy: The filing cites most-favored-nation pricing pressure and tariff threats of up to 100% on imported branded drugs. In December 2025, Gilead agreed to pause Section 232 tariffs for three years and to implement MFN prices in Medicaid for select products. Medicaid changes and expired ACA premium subsidies could also reduce patient coverage.
  • Wholesaler concentration: Historically, approximately 90% of U.S. gross product sales go to Cardinal Health, Cencora and McKesson. Their inventory swings can distort quarterly results.
  • Pipeline setbacks: The Phase 3 ASCENT-07 trial of Trodelvy missed its primary endpoint, and the filing says weaker Trodelvy revenue estimates could trigger future impairments. The FDA also placed a clinical hold on certain HIV trials, including WONDERS-1 and WONDERS-2.
  • Large spending commitments: The company plans to invest $32 billion in the U.S. through 2030. The filing warns of construction delays and cost inflation, and says debt-funded deals could pressure credit ratings.

What management is watching

  • 2026 outlook: Management expects continued product sales growth, bolstered by HIV demand. It expects this to be partly offset by U.S. policy developments and lower sales of Veklury and Cell Therapy.
  • Pipeline events: The company has over 50 clinical-stage programs. It expects FDA decisions on two first-line breast cancer therapies and an additional HIV treatment option. The Arcellx acquisition is anticipated to close during the second quarter of 2026.
  • Spending priorities: Management plans to keep investing in R&D internally and through partnerships, while focusing on disciplined operating expense management. Strategic priorities include long-acting HIV therapies, oncology and inflammation, and AI.
  • Patent runway: Settlements set the earliest generic Biktarvy entry in the U.S. at April 1, 2036, subject to standard acceleration provisions.
  • Capital return: Priorities include growing the dividend over time and repurchasing shares to offset dilution. A quarterly dividend of $0.82 per share was declared on February 10, 2026.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 30, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Gilead Sciences reported total revenues up 7% to $8.3 billion for the third quarter, led by HIV and Trodelvy. Diluted earnings per share fell to $1.94 from $2.43, mainly because of equity investment losses and higher expenses. The nine-month results show a net loss of $6.0 billion after the company's second-quarter acquisitions. In October, the government set a lower Medicare price for Biktarvy, effective in 2028.

How the business did

  • Sales: HIV product sales rose 18% to $6.2 billion, driven by higher average realized price, stronger demand in HIV prevention and favorable inventory dynamics. Biktarvy grew 10% and Descovy 49%. Trodelvy rose 42% to $506 million on higher demand.
  • Weak spots: Veklury (COVID-19) fell 69% to $86 million on fewer COVID-19 hospitalizations. Cell Therapy fell 18% to $355 million, which the company attributes to ongoing competitive headwinds.
  • Profit: Third-quarter net income was $2.4 billion versus $3.1 billion a year earlier. Net losses on equity securities replaced prior-year gains, and operating expenses and income tax expense rose. Product gross margin improved to 81.0% from 78.6%, driven by the expiration of a royalty-related obligation.
  • Unusual items for the nine months: Acquired in-process research and development (IPR&D, the cost of buying drugs still in development) was $11.3 billion. That included $7.0 billion for Arcellx and $3.1 billion for Tubulis. The company also took a $1.75 billion impairment after discontinuing the EVOKE-03 lung cancer trial.
  • Cash: Nine-month operating cash flow was $11,152 million versus $6,692 million. Cash and cash equivalents were $6.4 billion. A quarterly dividend of $0.82 per share was declared in October.

What management is watching

  • Upcoming FDA decisions: The target action date for anito-cel in multiple myeloma is December 23, 2026, and for the once-weekly Yeztugo tablet it is February 2, 2027.
  • Spending: Research and development expenses rose 19% to $1.6 billion, and selling, general and administrative expenses rose 21% to $1.6 billion. Management cites integration costs from the acquisitions and higher HIV promotion.
  • Capital priorities: Investing in the pipeline, selective partnerships and deals, growing the dividend, and share repurchases to offset dilution. The company says it can meet its capital needs for the next 12 months and beyond. These sections give no full-year financial outlook.

New or changed risks

  • Biktarvy price cut: The Centers for Medicare and Medicaid Services completed setting the Maximum Fair Price (the government-negotiated Medicare price) for Biktarvy in October 2026, effective January 2028. The filing says this will also bring higher Medicaid rebates, lower 340B ceiling prices and lower reimbursement.
  • Pricing models: In September 2026, a final rule created the GLOBE Model, which links certain Medicare Part B rebates to foreign prices, beginning in April 2027. A companion Part D model, GUARD, has been proposed. The company says the specifics are still evolving.
  • Tariffs: A 100% tariff on patented pharmaceuticals began to take effect in July 2026. The company's long-term impact is uncertain, given exemptions and possible changes, and the filing says an exemption is not guaranteed.
  • U.S. investment: A new risk factor covers the initiative to invest $32 billion in the U.S. through 2030, citing construction delays, cost inflation and regulatory inspections.

Follow GILD in Kortex

The Kortex app shows GILD's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.